1Moghimi SM, Hunter AC,Murray JC.Long-circulating and target-specific nanoparticles:theory to practice[J]. Pharmacological Reviews,2001,53:283-318.
2Moghimi SM,Porter C J, Muir IS,et al.Non-phagocytic uptake of intravenously injected microspheres in rat spleen-influence of particle- size and hydrophilic coating[J]. Biophysical Research Commmunications, 1991,177 : 861-866.
3Maeda H, Wu J, Sawa T,et al.Tumor vascular permeability and the EPR effect in macromolecular therapeutics:a review [J].Journalof Controlled Release, 2000,65 : 271 -284.
5Y Mizushima,T Ikoma,J Tanaka et al. J. Control. Release. ,2006,110(2) :260-265.
6K Nagasaki,T Ikoma,S Katsuda et al. J. Vet. Med. Sci. ,2009, 71 (6) :729-736.
7Kundu B;Soundrapandian C;Nandi SK et al. Development of new localized drug delivery system based on ceftriaxone-sulbactam composite drug impregnated porous hydroxyapatite: a systematic approach for in vitro and in vivo animal trial. Pharm Res. 2010,27(8): 1659-1676.
10Shanthi P M S,Ashok M,Balasubramanian T,et al.Synthesis and characterization of nano-hydroxyapatite at ambient temperature using cationic surfactant[J].Materials Letters,2009,63(24/25):2123-2125.
